Jacobson Pharma Announces FY2022 Interim Results
Robust Growth of 11.6% in Generics Business Amidst the Pandemic; Confident about Sustaining Strong Growth Momentum Declares Interim Dividend of HK1.2 Cents Per Share; A 50% Growth Compared to FY2021 Interim HONG KONG SAR – Media OutReach – 26 November 2021 – Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs […]